Eli Lilly has finalized its acquisition of Centessa Pharmaceuticals, a company developing orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders. This acquisition strengthens Lilly's neuroscience portfolio, aiming to address severe sleep disruptions that impact brain health and quality of life. Lilly plans to rapidly develop Centessa's clinical-stage treatments, potentially expanding options for patients with narcolepsy and related conditions. The move aligns with Lilly's broader mission to innovate in challenging medical areas and improve patient outcomes globally.
President Trump highlighted the creation of over 2,600 manufacturing jobs in Pennsylvania during a visit to the Mack Trucks facility. He credited his administration's policies, including rolling back stringent fuel emissions regulations, for boosting...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Illumina appointed Dr. Daniel M. Skovronsky, Chief Scientific and Product Officer at Eli Lilly, to its Board of Directors. His expertise in drug discovery and clinical development aligns with Illumina's focus on genomics and multiomics innovation. Th...
New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76%...
The High Court of Justice of England and Wales has approved Eli Lilly's acquisition of Centessa Pharmaceuticals for $38 per share plus potential milestone payments, valuing the deal at about $7.8 billion. The transaction will close on June 24, 2026, ...
